clofoctol

01/01/1985 - "Clinical study on the efficacy of clofoctol in the treatment of infectious respiratory diseases."
01/01/2023 - "Most of the clinical studies conducted on clofoctol concern the treatment of respiratory diseases in children. "

11/01/2018 - "Notably, clofoctol is already approved for clinical treatment of pulmonary infections caused by Gram-positive bacterial pathogens; hence, this drug has considerable clinical potential as an antivirulence agent for the treatment of P. "
11/01/1986 - "[Clinical efficacy of clofoctol in treating odontogenic infections]."
01/01/1985 - "Treatment of ear, nose and throat infections with clofoctol."
02/21/2023 - "Overall, this observation supports the development of inhaled clofoctol-colistin formulations for the treatment of difficult-to-treat airway infections caused by Gram-negative pathogens. "
02/21/2023 - "Here, a strong synergistic activity of the colistin-clofoctol combination against colistin-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii isolates is reported, supporting the development of clofoctol-colistin formulations for the therapy of difficult-to-treat airways infections caused by these Gram-negative pathogens."

10/01/2014 - "Our findings revealed clofoctol as a novel activator of the unfolded protein response pathways and a promising inhibitor of prostate cancer. "
10/01/2014 - "Clofoctol also inhibited prostate cancer xenograft growth in vivo without apparent toxicity. "
10/01/2014 - "Activation of unfolded protein response pathways by clofoctol led to the inhibition of protein translation in cells and the induction of G1 cell cycle arrest in prostate cancer cells. "
10/01/2014 - "The antibacterial drug clofoctol was identified as a novel inhibitor of prostate cancer cell proliferation. "
01/01/2018 - "The aim of this study is to evaluate the synergistic inhibitory mechanisms of clofoctol and sorafenib in the treatment of prostate cancer. "

01/01/2019 - "Moreover, growth of tumors was inhibited obviously in vivo after clofoctol treatment especially in primary patient-derived xenografts (PDXs) and transgenic xenografts. "
10/01/2014 - "As clofoctol has been used in the clinic for years, it is ready for clinical evaluation as a novel antiprostate cancer drug candidate."
01/01/2018 - "In this study, we investigated the anti-tumor effects of clofoctol in combination with sorafenib in vitro and in vivo. "
01/01/2018 - "In addition, combination therapy with clofoctol and sorafenib markedly inhibited the growth of prostate cancer xenograft tumors, compared with clofoctol or sorafenib alone. "

08/01/2012 - "The aim of the study was to examine the In vitro susceptibility of clinical isolates of respiratory pathogens to clofoctol compared with amoxicillin and erythromycin, and to characterize the pharmacokinetic/pharmacodynamic (PK/PD) relationships of clofoctol using a murine pneumonia infection model. "